Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295

Citations Over Time

Abstract

Inhibition of mitotic kinesins represents a novel approach for the discovery of a new generation of anti-mitotic cancer chemotherapeutics. We report here the discovery of the first potent and selective inhibitor of centromere-associated protein E (CENP-E) 3-chloro-N-{(1S)-2-[(N,N-dimethylglycyl)amino]-1-[(4-{8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl}phenyl)methyl]ethyl}-4-[(1-methylethyl)oxy]benzamide (GSK923295; 1), starting from a high-throughput screening hit, 3-chloro-4-isopropoxybenzoic acid 2. Compound 1 has demonstrated broad antitumor activity in vivo and is currently in human clinical trials.

Related Papers

• → Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors(2009)29 cited
• Note Synthesis and antibacterial activity of benzamides and sulfonamide derived from 2- amino-5-bromo/nitropyridine against bacterial strains isolated from clinical patients(2011)
• → N-(4-Methylphenyl)benzamide(2007)7 cited
• → Synthesis of N‐(2,3‐dihydro‐1‐[14C]methyl‐2‐oxo‐5‐phenyl‐1H‐1,4‐benzodiazepin‐3‐yl)‐benzamide and N‐(2,3‐dihydro‐1‐[14C]methyl‐2‐oxo‐5‐phenyl‐1H‐1,4‐benzodiazepin‐3‐yl)‐N‐[14C]methyl‐benzamide as novel carbon‐14 labelled CCK antagonists(2002)6 cited
• → N-(2,4-Dichlorophenyl)benzamide(2008)6 cited